Statins in chronic renal disease;Estatinas na doença renal crônica

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue SUPPL. 5, 2005, Pages 45-49

  Ferreira, Soraia R C ^a   Rocha, Aloísio M ^a   Saraiva, José Francisco K ^a  

^a Instituto de Ciências Biológicas e Químicas   (Brazil)

Author keywords

Dyslipidemia; End stage renal disease; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; META ANALYSIS; MORBIDITY; MORTALITY; RENAL PROTECTION; SYSTEMATIC REVIEW;

EID: 31144471373     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169.
2. Mathur S, Devaraj S and Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002; 11: 141-147.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000; 35 (4 suppl 1): S117-S131.
4. Anavekar NS and Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 (s 92): S 11.
5. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001; 38 (6): 1398-1407.
6. Ferreira SR, Moises VA, Tavares A, Pacheco-Silva A. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 2002; 74 (11): 1580-7.
7. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278.
8. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular fitration in diabetic nephropathy. Am J Med 1983; 74: 256.
9. Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15 (8): 2161-8.
10. Barenbrock M, Kosch M, Joster E, Kisters K, Rahn KH, Hausberg M. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20 (1): 79-84.
11. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17 (8): 1513-7.
12. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16 (11): 2152-7.
13. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35 (3): 469-76.
14. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213-1217.
15. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261.
16. Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 2001; 276: 15090.
17. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908.
18. Yamashita T, Kawahsim S, Miwa Y, et al. A 3-hydroxy-3methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hyperten 2002; 20: 2465-73.
19. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138 (2): 98-104
20. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605.
21. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220.
22. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. Journal of Clinical Pathology. In Press 2004.
23. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565.
24. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260.
25. Konstadinidou I, Boletis JN, Perrea D, Triantafyllou A, Filiopoulos V, Stamataki E, Kostakis A, Stathakis C: Beneficial effects of fluvastatin on progreeive renal allograft dysfunction. Transplant Proc 2003; 35: 1364-1367.
26. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361(9374): 2024-31.
27. Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant 2004; 19 (9): 2378-86.
28. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39 (2): 283-90.
29. Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44 (5): 1124-9.
30. Olbricht CJ, Wanner C, Thiery J, Basten A, for the Simvastatin In Nephrotic Syndrome Study Group. Simvastatin In Nephrotic Syndrome. Kidney Int 1999; 56 (Suppl 71): S113-S116.
31. Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76 (2): 97A-101A.
32. III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção de Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol 2001; 77 (Supl III): 1-48
33. Diretrizes Brasileiras de Doença Renal Crônica. J Bras Nefrol 2004; XXVI (3) Supl 1.
34. Warner C et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Méd. 2005;353:238-48.